ArticleCancer cell2017
Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.
Article in Cancer cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 283 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
283 citing papers in PubMed, 3 syntheses or guidelines pooled it, 434 citations in OpenAlex.
- Immunoconjugates in cervical cancer: a bibliometric and thematic mapping analysis of global research trends, 2015-2024.Frontiers in oncology · 2026Pooled it
- IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review.Molecular oncology · 2024Pooled it
- Survival and clinicopathological significance of B7-H3 in bladder cancer: a systematic review and meta-analysis.BMC urology · 2024Pooled it
- A whole-body imaging technique for tumor-specific diagnostics and screening of B7H3-targeted therapies.The Journal of clinical investigation · 2025Trial
- Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma.Cell reports. Medicine · 2026Article
- Enhancing the efficacy of B7-H3-targeting antibody-drug conjugate DS-7300a in TP53-deficient tumors by inducing ferroptosis.Oncogene · 2026Article
- Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial.Nature medicine · 2026Article
- mTORC1 activation induces B7-H3-dependent metabolic reprogramming in renal cell carcinoma (RCC).Oncogene · 2026Article
- AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins.Nature communications · 2026Article
- Mapping B7-H3 in the tumour microenvironment: a systematic review of stromal, vascular and immune expression.British journal of cancer · 2026Review
- Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Fluorescence-Guided Surgery of Rhabdomyosarcoma Using a B7-H3 Targeted Antibody-Fluorophore Conjugate.Molecular pharmaceutics · 2026Article
- Cellular immunotherapy in melanoma: the next frontier in cancer treatment.Journal of experimental & clinical cancer research : CR · 2026Review
- LGALS1-CD276 Paracrine axis between tumor and endothelial cells promotes tumor angiogenesis and progression in bladder cancer.Cell death and differentiation · 2026Article
- An Implantable Scaffold Sequentially Releasing STING Agonist and B7-H3 Antibody for Bone Metastasis Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy.Cell reports. Medicine · 2026Article
- A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma.Molecular cancer therapeutics · 2026Article
- Advanced CD276-Targeting Dual-Payload Antibody-Drug Conjugates for Cancer Therapy.Cancer research communications · 2026Article
- Evaluation of the Clinical Value of the Serological Markers CD276 and DKK3 in Gastric Cancer: A Case-Control Study.Diagnostics (Basel, Switzerland) · 2026Article
223 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors at 7 institutions in 1 country.
Funding
Abstract
Targeting the tumor vasculature with antibody-drug conjugates (ADCs) is a promising anti-cancer strategy that in order to be realized must overcome several obstacles, including identification of suitable targets and optimal warheads. Here, we demonstrate that the cell-surface protein CD276/B7-H3 is broadly overexpressed by multiple tumor types on both cancer cells and tumor-infiltrating blood vessels, making it a potentially ideal dual-compartment therapeutic target. In preclinical studies CD276 ADCs armed with a conventional MMAE warhead destroyed CD276-positive cancer cells, but were ineffective against tumor vasculature. In contrast, pyrrolobenzodiazepine-conjugated CD276 ADCs killed both cancer cells and tumor vasculature, eradicating large established tumors and metastases, and improving long-term overall survival. CD276-targeted dual-compartment ablation could aid in the development of highly selective broad-acting anti-cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.